BSF Enterprise PLC

("BSF" or the "Company")

Admission of Placing Shares and Subscription Shares

Further to the Company's announcements of 29 March and 12 April  2023 (the "Fundraising Announcements"), the Shares (being 16,317,648 Placing Shares, 50,000 ordinary shares issued following the exercise of warrants and 617,613 of the Subscription Shares (which excludes the Second Tranche Shares)), were admitted to listing on the Official List (standard listing segment) and to trading on the London Stock Exchange's main market for listed securities ("Admission") effective at 8.00 am today.

Capitalised terms used in this announcement have the same meanings as those ascribed to them in the Fundraising Announcements.

Total Voting Rights

Following Admission, the total number of ordinary shares in the Company in issue will be 102,972,198. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure and Transparency Rules.

For further enquiries, please visit www.bsfenterprise.com or contact:

Notes to Editors

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice. 

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.